FAQs
1. How do costs of liquid biopsies compare?
Liquid biopsy tests currently cost between $949 and $15,562 per test. These prices often exceed the relative effectiveness of a colonoscopy, which averages around $9,037. To reach a cost-effectiveness threshold of $100,000 per life year gained compared to traditional screening, prices would likely need to drop to a range of $56 to $324.
2. What causes false results in liquid biopsies?
False negatives arise from low ctDNA shedding or assay limits on complex variants like amplifications, while false positives stem from clonal hematopoiesis (mutations in white blood cells) or tumor heterogeneity. Better validation and benchmarking improve accuracy.
3. What other body fluids are used in liquid biopsies?
Liquid biopsies now analyze urine, saliva, cerebrospinal fluid (CSF), and pleural effusions—beyond blood—for CNS tumors, head/neck cancers, and NSCLC where blood sensitivity falls short, thereby enhancing targeted therapy detection. AI integrates these multimodal data for improved early detection and monitoring.
Reference
1. Ilié, M., & Hofman, P. (2016). Pros: Can tissue biopsy be replaced by liquid biopsy?. Translational lung cancer research, 5(4), 420.
2. Palmirotta, R., Lovero, D., Cafforio, P., et al. (2018). Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Therapeutic advances in medical oncology, 10, 1758835918794630.
3. Cescon, D. W., Bratman, S. V., Chan, S. M., et al. (2020). Circulating tumor DNA and liquid biopsy in oncology. Nature cancer, 1(3), 276-290.
4. Stoecklein, N. H., Fluegen, G., Guglielmi, R., et al. (2023). Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis. Molecular cancer, 22(1), 181.
5. Zhou, B., Xu, K., Zheng, X., et al. (2020). Application of exosomes as liquid biopsy in clinical diagnosis. Signal transduction and targeted therapy, 5(1), 144.
6. Lee, H., Park, C., Na, W., et al. (2020). Precision cell-free DNA extraction for liquid biopsy by integrated microfluidics. NPJ precision oncology, 4(1), 3.
7. Connal, S., Cameron, J. M., Sala, A., et al. (2023). Liquid biopsies: the future of cancer early detection. Journal of translational medicine, 21(1), 118.
8. Kilgour, E., Rothwell, D. G., Brady, G., et al. (2020). Liquid biopsy-based biomarkers of treatment response and resistance. Cancer cell, 37(4), 485-495.
9. Wang, Z., Bai, J., Jiang, D., et al. (2024). Liquid biopsy for monitoring minimal residual disease in colorectal cancer: a promising approach with clinical implications. Clinical Surgical Oncology, 3(3), 100056.
10. Raez, L. E., Brice, K., Dumais, K., Lopez-Cohen, A., Wietecha, D., Izquierdo, P. A., … & Powery, H. W. (2023). Liquid biopsy versus tissue biopsy to determine front line therapy in metastatic non-small cell lung cancer (NSCLC). Clinical Lung Cancer, 24(2), 120-129.
11. Fagery, M., Khorshidi, H. A., Wong, S. Q., et al. (2023). Health economic evidence and modeling challenges for liquid biopsy assays in cancer management: a systematic literature review. Pharmacoeconomics, 41(10), 1229-1248.
12. Mannelli, C. (2019). Tissue vs liquid biopsies for cancer detection: ethical issues. Journal of bioethical inquiry, 16(4), 551-557.
13. Yu, S. C., Choy, L. L., & Lo, Y. D. (2023). ‘Longing’for the next generation of liquid biopsy: the diagnostic potential of long cell-free DNA in oncology and prenatal testing. Molecular Diagnosis & Therapy, 27(5), 563-571.
14. Nassar, A., Cashman, K., Rao, S., et al. (2023). Liquid biopsy for non-invasive monitoring of patients with kidney transplants. Frontiers in Transplantation, 2, 1148725.
15. Han, D., Li, R., Shi, J., et al. (2020). Liquid biopsy for infectious diseases: a focus on microbial cell-free DNA sequencing. Theranostics, 10(12), 5501.
16. Heuser, M., Thol, F., & Ganser, A. (2016). Clonal hematopoiesis of indeterminate potential: a risk factor for hematologic neoplasms. Deutsches Ärzteblatt International, 113(18), 317.
17. Ntzifa, A., & Lianidou, E. (2023). Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis. Critical reviews in clinical laboratory sciences, 60(8), 573-594.
18. Chen, M., & Zhao, H. (2019). Next-generation sequencing in liquid biopsy: cancer screening and early detection. Human genomics, 13(1), 34.
19. Ginghina, O., Hudita, A., Zamfir, M., et al. (2022). Liquid biopsy and artificial intelligence as tools to detect signatures of colorectal malignancies: a modern approach in patient’s stratification. Frontiers in oncology, 12, 856575.